Radioimmunoguided imaging of prostate cancer foci with histopathological correlation

被引:36
作者
Ellis, RJ
Kim, EY
Conant, R
Sodee, DB
Spirnak, JP
Dinchman, KH
Beddar, S
Wessels, B
Resnick, MI
Kinsella, TJ
机构
[1] Univ Hosp Cleveland, Dept Radiat Oncol, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland, Dept Radiol, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Dept Urol, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Sch Med, Dept Radiol, Cleveland, OH USA
[5] Case Western Reserve Univ, Sch Med, Div Urol, Metrohlth Med Ctr, Cleveland, OH USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2001年 / 49卷 / 05期
关键词
prostate; brachytherapy; ProstaScint; radioimmunoguided; IMRT;
D O I
10.1016/S0360-3016(00)01582-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We have previously presented a technique that fuses ProstaScint and pelvic CT images for the purpose of designing brachytherapy that targets areas at high risk for treatment failure. We now correlate areas of increased intensity seen on ProstaScint-CT fusion images to biopsy results in a series of 7 patients to evaluate the accuracy of this technique in localizing intraprostatic disease. Methods and Materials: The 7 patients included in this study were evaluated between June 1998 and March 29, 1999 at Metrohealth Medical Center and University Hospitals of Cleveland in Cleveland, Ohio. ProstaScint and CT scans of each patient were obtained before transperineal biopsy and seed implantation. Each patient's prostate gland was biopsied at 12 separate sites determined independently of Prostascint-CT scan results. Results: When correlated with biopsy results, our method yielded an overall accuracy of 80 %: with a sensitivity of 79 %, a specificity of 80 %, a positive predictive value of 68 %, and a negative predictive value of 88 %. Conclusion: The image fusion of the pelvic CT scan and ProstaScint scan helped identify foci of adenocarcinoma within the prostate that correlated well with biopsy results. These data may be useful to escalate doses in regions containing tumor by either high-dose rate or low-dose rate brachytherapy, as well as by external beam techniques such as intensity modulated radiotherapy (IMRT). (C) 2001 Elsevier Science Inc.
引用
收藏
页码:1281 / 1286
页数:6
相关论文
共 24 条
[1]   Should brachytherapy be considered a therapeutic option in localized prostate cancer? [J].
Blasko, JC ;
Ragde, H ;
Luse, RW ;
Sylvester, JE ;
Cavanagh, W ;
Grimm, PD .
UROLOGIC CLINICS OF NORTH AMERICA, 1996, 23 (04) :633-+
[2]  
Chang SS, 2000, CANCER-AM CANCER SOC, V88, P407, DOI 10.1002/(SICI)1097-0142(20000115)88:2<407::AID-CNCR23>3.3.CO
[3]  
2-S
[4]   Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated? [J].
D'Amico, AV ;
Davis, A ;
Vargas, SO ;
Renshaw, AA ;
Jiroutek, M ;
Richie, JP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (03) :587-590
[5]  
DONOHUE RE, 1991, UROL CLIN N AM, V18, P449
[6]   Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy [J].
Ellis, RJ ;
Sodee, DB ;
Spirnak, JP ;
Dinchman, KH ;
O'Leary, AW ;
Samuels, MA ;
Resnick, MI ;
Kinsella, TJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :683-687
[7]  
Faulhaber PF, 2000, J NUCL MED, V41, p116P
[8]   111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy [J].
Kahn, D ;
Williams, RD ;
Manyak, MJ ;
Haseman, MK ;
Seldin, DW ;
Libertino, JA ;
Maguire, RT .
JOURNAL OF UROLOGY, 1998, 159 (06) :2041-2046
[9]   The prostate: MR imaging and spectroscopy - Present and future [J].
Kurhanewicz, J ;
Vigneron, DB ;
Males, RG ;
Swanson, MG ;
Yu, KK ;
Hricak, H .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2000, 38 (01) :115-+
[10]  
Leisure G P, 1997, J Nucl Med Technol, V25, P115